2 min read

Global Health Moat Analysis: Score & Risks

Moat Note · First-pass

Global Health Ltd.

A first-pass moat teardown of Global Health Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.

Moat & Margin16 Aug 2026 First-pass · ~3 min
5.07 / 10
NARROWProcess/Data-led

First-pass narrow read — primary edge in Network Effects. Provisional, single-pass evidence.

Provisional score · subject to modification based on new evidence

Global Health Ltd. scores 5.07 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.

The teardown

Seven dimensions of moat

Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.

D1Network Effects6
M · Mechanism Verified verbatim

“550+ Doctors on-boarded in FY26 across Medanta network hospitals out of which 249 doctors were on-boarded at newly launched Noida facility”

Global Health Ltd. · Investor Presentation · p.6
D3Cost Advantage5.5
No verified filing quote surfaced for this dimension in the first-pass evidence sweep.
D2Switching Costs4.8
M · Mechanism Verified verbatim

“our board has approved a long-term lease agreement for a newly built 110 bedded hospital in Ranchi”

Global Health Ltd. · Earnings Call · p.4
D4Price Discretion4.8
M · Mechanism Verified verbatim

“Increasing PPP and scheme business has been marginally ARPOB-dilutive, but it has been offset by growing contribution from cancer and changing case mix.”

Global Health Ltd. · Earnings Call · p.5
D6Efficient Scale4.8
M · Mechanism Verified verbatim

“Mr. Ratnasami Venkatesh, resigned as Non-Executive Nominee Director w.e.f. November 14, 2024.”

Global Health Ltd. · Xbrl Text
D5Intangible Assets4.7
M · Mechanism Verified verbatim

“A one-time provision of ₹499 millions was made towards stamp duty, with no consideration issued as MHPL was a wholly owned subsidiary.”

Global Health Ltd. · Annual Report · p.62
D7Counter-PositioningExcluded
Excluded for this archetype.
D8Ungoverned RiskUnscored · Layer 2.5

D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.

The barrier gate

The barrier gate — first-pass

Replication — can a rival copy it?6.0
How hard it is for a rival to copy the edge (first-pass estimate).
Bypass — can a rival route around it?5.0
How easily a rival can route around the edge (first-pass estimate).

Effective barrier 5 — below 6, so the band is capped narrow. First-pass estimate.

What would change our mind
  1. Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.

  2. The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.

  3. Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.

First-pass note — provisional single-pass MoatSCORE 6.0 read, not the full deep dive. Educational research, not investment advice; no buy/sell recommendation, no price target. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser.